We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+17.98%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.89B
AUM Growth
+$155M
Cap. Flow
-$17.4M
Cap. Flow %
-0.92%
Top 10 Hldgs %
59.01%
Holding
53
New
4
Increased
8
Reduced
11
Closed
8

Top Buys

Rank Stock Value
1
BIOA
BioAge Labs
BIOA
+$32.7M
2
RNAM
Avidity Biosciences
RNAM
+$27.1M
3
CRBP icon
Corbus Pharmaceuticals
CRBP
+$17.9M
4
MBX
MBX Biosciences
MBX
+$16M
5
ANAB icon
AnaptysBio
ANAB
+$11.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$19.8M
2
CGEM icon
Cullinan Oncology
CGEM
+$19.6M
3
ACLX
Arcellx
ACLX
+$18.3M
4
BHVN icon
Biohaven
BHVN
+$15.6M
5
INSM icon
Insmed
INSM
+$12.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.56B
$428M 22.71%
8,494,151
– –
PCVX icon
2
Vaxcyte
PCVX
$7.65B
$114M 6.06%
1,000,000
-100,000
-9% -$9.01M
ACLX
3
DELISTED
Arcellx
ACLX
$104M 5.54%
1,250,000
-275,000
-18% -$18.3M
LBPH
4
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$93M 4.93%
2,790,462
– –
EWTX icon
5
Edgewise Therapeutics
EWTX
$4.28B
$90.9M 4.82%
3,406,534
+400,000
+13% +$7.96M
EYPT icon
6
EyePoint Inc
EYPT
$999M
$66.5M 3.53%
8,325,000
– –
RAPP
7
Rapport Therapeutics
RAPP
$1.96B
$60.2M 3.19%
2,940,921
+638
+0% +$13.7K
CRNX icon
8
Crinetics Pharmaceuticals
CRNX
$8.88B
$56.2M 2.98%
1,100,000
-250,000
-19% -$12.9M
PRAX icon
9
Praxis Precision Medicines
PRAX
$8.11B
$50.1M 2.65%
870,000
+185,000
+27% +$9.99M
CRBP icon
10
Corbus Pharmaceuticals
CRBP
$165M
$49M 2.6%
2,375,000
+350,000
+17% +$17.9M
RNAM
11
DELISTED
Avidity Biosciences
RNAM
$48.2M 2.56%
1,050,000
+625,000
+147% +$27.1M
JANX icon
12
Janux Therapeutics
JANX
$912M
$47.7M 2.53%
1,050,000
– –
BBIO icon
13
BridgeBio Pharma
BBIO
$16.4B
$47.3M 2.51%
1,858,351
– –
NAMS icon
14
NewAmsterdam Pharma
NAMS
$3.26B
$41M 2.17%
2,470,000
+170,000
+7% +$2.94M
CNTA
15
DELISTED
Centessa Pharmaceuticals
CNTA
$41M 2.17%
2,561,600
+950,000
+59% +$11.6M
MRUS
16
DELISTED
Merus
MRUS
$37M 1.96%
740,000
-100,000
-12% -$5.22M
CGON icon
17
CG Oncology
CGON
$6.1B
$36.8M 1.95%
975,000
– –
INSM icon
18
Insmed
INSM
$22.4B
$36.5M 1.94%
500,000
-175,000
-26% -$12.9M
BMEA icon
19
Biomea Fusion
BMEA
$88.2M
$36.1M 1.91%
3,570,872
– –
AXSM icon
20
Axsome Therapeutics
AXSM
$11.7B
$35.9M 1.91%
400,000
– –
BIOA
21
BioAge Labs
BIOA
$986M
$33.9M 1.8%
+1,629,529
New +$32.7M
BBOT
22
BridgeBio Oncology
BBOT
$659M
$30.4M 1.61%
2,909,000
– –
PHVS icon
23
Pharvaris
PHVS
$2.28B
$27.2M 1.44%
1,466,460
– –
ABVX
24
Abivax
ABVX
$10.4B
$24.5M 1.3%
2,130,000
– –
ALMS
25
Alumis Inc
ALMS
$3.36B
$22.9M 1.22%
2,147,396
-4
-0% -$49
1
2 3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2024 Portfolio in Review

As of Q3 2024, Cormorant Asset Management held 53 positions worth $1.89B, up 8.9% from $1.73B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Cormorant Asset Management's Q3 2024 filing shows 4 new, 8 increased, 11 reduced and 8 closed positions. Its largest new stake was BioAge Labs: 1,629,529 shares worth $33.9M. The largest sale was Sarepta Therapeutics, an estimated $19.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • Cormorant Asset Management's largest Q3 2024 buy was BioAge Labs: 1,629,529 shares worth $33.9M.
  • Cormorant Asset Management added most to Avidity Biosciences in Q3 2024, an estimated $27.1M increase.
  • Cormorant Asset Management's biggest Q3 2024 reduction was Arcellx, cutting an estimated $18.3M.
  • Cormorant Asset Management fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $19.8M.
  • Cormorant Asset Management's ten largest holdings make up 59% of its $1.89B portfolio in Q3 2024.
  • Cormorant Asset Management opened 4 new positions and closed 8 in Q3 2024.
  • Cormorant Asset Management's portfolio value rose 8.9% quarter-over-quarter to $1.89B.

Based on Cormorant Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.